Natera: Results Of DEFINE-HT Clinical Trial Shows Prospera Heart Is Predictive Of Clinical Outcomes And Outperforms Biopsy In Predicting Graft Dysfunction
Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides
Dow Boosted by Honeywell, Sherwin-Williams While S&P and Nasdaq Seesaw
Earnings Call Summary | Regeneron Pharmaceuticals(REGN.US) Q1 2025 Earnings Conference
Regeneron Projects Pivotal Data Readouts for Multiple Programs in 2025
Piper Sandler Maintains Neutral on Biogen, Lowers Price Target to $115
Biogen Analyst Ratings
Regeneron Drops as Eylea Drives Q1 Miss
Gilead To Present New Research To EASL Congress
Illumina Analyst Ratings
Today's Pre-Market Movers and Top Ratings | SPOT, NVO, SOFI, and More
NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Regeneron Pharmaceuticals Q1 Adj. EPS $8.22 Misses $8.82 Estimate, Sales $3.03B Miss $3.29B Estimate
Earnings Scheduled For April 29, 2025
Here's the Major Earnings Before the Open Tomorrow
SA Analyst Downgrades: TSLA, AAPL, T, PG, HPE, GILD, LRCX, ARCC
Insights Into Regeneron Pharmaceuticals's Upcoming Earnings
Neurocrine Biosciences Analyst Ratings
Regeneron Pharmaceuticals Announces The Upcoming Presentation Of 27 Abstracts, Including Eight Oral Presentations On EYLEA HD Injection 8 MG . Data Will Be Presented at the Association For Research In Vision and Ophthalmology 2025 Annual Meeting May 4...
Regeneron Pharmaceuticals Announces That The European Commission Has Granted Conditional Marketing Approval Of Lynozyfic To Treat Adults With Relapsed And Refractory Multiple Myeloma